Hudock Capital Group LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,921 shares of the medical research company’s stock after purchasing an additional 10 shares during the quarter. Hudock Capital Group LLC’s holdings in Amgen were worth $330,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Bank of New York Mellon Corp grew its stake in shares of Amgen by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock worth $1,403,676,000 after purchasing an additional 195,200 shares during the period. Legal & General Group Plc lifted its position in shares of Amgen by 2.5% during the 2nd quarter. Legal & General Group Plc now owns 3,721,359 shares of the medical research company’s stock valued at $640,938,000 after buying an additional 90,615 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Amgen by 2.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 2,962,595 shares of the medical research company’s stock valued at $510,248,000 after buying an additional 67,815 shares in the last quarter. UBS Asset Management Americas Inc. lifted its position in shares of Amgen by 3.1% during the 1st quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock valued at $446,250,000 after buying an additional 81,362 shares in the last quarter. Finally, Swiss National Bank lifted its position in shares of Amgen by 26.5% during the 1st quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock valued at $432,490,000 after buying an additional 551,600 shares in the last quarter. 78.20% of the stock is currently owned by institutional investors and hedge funds.

In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $185.95, for a total transaction of $283,573.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Carbonnel Francois De sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. 0.19% of the stock is owned by insiders.

A number of research analysts have recently issued reports on the company. Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Royal Bank Of Canada decreased their target price on Amgen from $192.00 to $188.00 and set a “sector perform” rating on the stock in a research report on Thursday, October 26th. BMO Capital Markets lowered Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 target price on the stock. in a research report on Friday, July 21st. They noted that the move was a valuation call. Credit Suisse Group reiterated a “neutral” rating and set a $186.00 target price (up previously from $177.00) on shares of Amgen in a research report on Friday, September 29th. Finally, Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $203.00 target price on shares of Amgen in a research report on Thursday, September 7th. Thirteen investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. Amgen has an average rating of “Buy” and a consensus target price of $190.03.

Amgen Inc. (NASDAQ AMGN) opened at $171.50 on Tuesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 6.07 and a quick ratio of 5.72. The stock has a market capitalization of $125,110.70, a PE ratio of 13.70, a PEG ratio of 2.50 and a beta of 1.37. Amgen Inc. has a 52 week low of $138.83 and a 52 week high of $191.10.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the consensus estimate of $3.11 by $0.16. The firm had revenue of $5.77 billion during the quarter, compared to analysts’ expectations of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The firm’s revenue was down .7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.02 earnings per share. sell-side analysts expect that Amgen Inc. will post 12.66 earnings per share for the current fiscal year.

Amgen announced that its Board of Directors has authorized a share buyback plan on Wednesday, October 25th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to buy shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Friday, November 17th will be paid a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.68%. The ex-dividend date of this dividend is Thursday, November 16th. Amgen’s payout ratio is 41.63%.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/14/hudock-capital-group-llc-has-330000-stake-in-amgen-inc-amgn.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.